Combination therapy
View Patent ↗Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
1. A composition comprising:
a) a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate, a dimesylate salt of (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethyl benzoate, or a dimesylate salt of (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate; and
b) latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2α , fluprostenol, or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 , wherein the composition comprises latanoprost or a pharmaceutically acceptable salt thereof.
3. The composition of claim 1 , wherein the composition comprises a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
4. The composition of claim 1 , wherein the composition comprises a dimesylate salt of (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
5. The composition of claim 1 , wherein the composition comprises a dimesylate salt of (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
6. The composition of claim 1 , wherein the composition comprises a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate, and latanoprost or a pharmaceutically acceptable salt thereof.
7. The composition of claim 1 , wherein the composition further comprises at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar, a sugar alcohol, or a surfactant.
8. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject a composition comprising:
a) a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethyl benzoate, a dimesylate salt of (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethyl benzoate, or a dimesylate salt of (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate; and
b) latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2α , fluprostenol, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the composition comprises latanoprost or a pharmaceutically acceptable salt thereof.
10. The method of claim 8 , wherein the composition comprises a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
11. The method of claim 8 , wherein the composition comprises a dimesylate salt of (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
12. The method of claim 8 , wherein the composition comprises a dimesylate salt of (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
13. The method of claim 8 , wherein the composition comprises a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate, and latanoprost or a pharmaceutically acceptable salt thereof.
14. The method of claim 8 , wherein the composition further comprises at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar, a sugar alcohol, or a surfactant.
15. The method of claim 8 , wherein the ocular disorder is glaucoma.
16. The method of claim 10 , wherein the ocular disorder is glaucoma.
17. The method of claim 13 , wherein the ocular disorder is glaucoma.
18. The method of claim 8 , wherein the composition is administered topically to an eye of the subject.
19. The method of claim 16 , wherein the composition is administered topically to an eye of the subject.
20. The method of claim 17 , wherein the composition is administered topically to an eye of the subject.